Acarbose: Clinical Trials

39 trials of Acarbose, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 11 unknown, 3 terminated, 1 recruiting. 39 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 439Completed 24, Unknown 11, Terminated 3, Recruiting 1

Follow Acarbose: new trials by email Literature Review of Acarbose trials Research Report on Acarbose

Trials (filtered) newest first · largest first

All 39 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
Canagliflozin group, Sitagliptin, Acarbose - Type 2 Diabetes Mellitus, Cognitive Impairment
Phase 4RecruitingFudan University602024-08-192026-07-17
The Efficacy and Tolerability of Acarbose in Healthy Individuals
Acarbose Tablets 50mg - Tolerance, Side Effect
Phase 4CompletedAgelessRx152022-08-102023-07-27
Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents
Glucophage 500Mg Tablet, Acarbose Tablets, Sitagliptin tablet - Type2 Diabetes Mellitus
Phase 4UnknownPeking Union Medical College Hospital1802020-03-022020-02-27
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Alogliptin, Acarbose, Metformin - Type 2 Diabetes Mellitus
Phase 4CompletedSanofi12932019-06-292022-04-25
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
Sitagliptin, Acarbose - Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Phase 4UnknownChinese PLA General Hospital3002018-10-012018-07-27
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30 - Type 2 Diabetes Mellitus
Phase 4CompletedSanofi3842018-01-202022-04-25
Research of Intensive Metabolic Intervention Before Pregnancy in PCOS
Acarbose 100 MG, Exenatide, Orlistat - PCOS, Impaired Glucose Tolerance
Phase 4UnknownRenJi Hospital1602018-01-012017-12-26
A Phase IV Study in Drug-Naive Patients With T2DM in China
Dapagliflozin, Acarbose - Type 2 Diabetes Mellitus
Phase 4TerminatedAstraZeneca3042017-12-152021-12-07
Human Oral Detection of Glucose Olygomers
Acarbose - Healthy Volunteers
Phase 4CompletedOregon State University1572017-04-212023-02-21
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
INSULIN GLARGINE, metformin, acarbose - Diabetes Mellitus, Type 2
Phase 4CompletedSanofi8922016-09-092022-04-25
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
Acarbose, Vildagliptin - Diabetes Mellitus, Type 2, Obesity
Phase 4UnknownPeking University1002016-03-012016-12-21
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
Acarbose, Metformin, Saxagliptin - Type 2 Diabetes Mellitus
Phase 4UnknownFifth Affiliated Hospital, Sun Yat-Sen University1002015-12-012015-11-18
Treatment of Hypoglycemia Following Gastric Bypass Surgery
Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity
Phase 4CompletedZealand University Hospital112015-10-012018-03-07
the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin
premix insulin, metformin, Acarbose - Type 2 Diabetes
Phase 4UnknownShanghai 6th People's Hospital802014-12-012015-05-08
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
Gemigliptin, Acarbose - Endothelial Function, Type 2 Diabetes
Phase 4UnknownSeoul National University Hospital542014-09-012015-07-16
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
Saxagliptin, Acarbose - Type 2 Diabetes Mellitus
Phase 4CompletedAstraZeneca6892014-09-012017-04-14
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
Metformin, Voglibose, Acarbose - Type 2 Diabetes Mellitus
Phase 4CompletedTakeda4942014-05-092019-03-13
Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus
Mitiglinide, Acarbose - Type 2 Diabetes Mellitus
Phase 4CompletedZhongda Hospital2482014-05-012016-07-14
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
Glimepiride, Metformin, Pioglitazone - Diabetes Mellitus, Type 2
Phase 4TerminatedEli Lilly and Company1922014-02-012019-10-09
Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Sitagliptin and acarbose - Newly Diagnosed Type 2 Diabetes, Coronary Artery Disease
Phase 4CompletedWuhan General Hospital of Guangzhou Military Command662013-07-012015-08-18

Showing 20 of 39. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (27)  ·  Diabetes Mellitus (6)  ·  Glucose Intolerance (5)  ·  Coronary Artery Disease (2)  ·  Hyperglycemia (2)  ·  Insulin Resistance (2)  ·  Obesity (2)  ·  Acute Coronary Syndrome (1)  ·  Cardiovascular Diseases (1)  ·  Cognitive Dysfunction (1)  ·  Coronary Disease (1)  ·  Dyslipidemias (1)  ·  Hepatitis C, Chronic (1)  ·  Hypoglycemia (1)  ·  Kidney Diseases (1)

Sponsors

Sanofi (3)  ·  AstraZeneca (2)  ·  Novartis Pharmaceuticals (2)  ·  AgelessRx (1)  ·  Aichi Gakuin University (1)  ·  Bayer (1)  ·  Chinese PLA General Hospital (1)  ·  Eli Lilly and Company (1)  ·  Fifth Affiliated Hospital, Sun Yat-Sen University (1)  ·  Fudan University (1)  ·  Indiana University (1)  ·  Inje University (1)  ·  Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1)  ·  Karolinska Institutet (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

China (18)  ·  United States (5)  ·  South Korea (4)  ·  Taiwan (3)  ·  Austria (1)  ·  Canada (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Iran (1)  ·  Japan (1)  ·  Mexico (1)  ·  Puerto Rico (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Ashraf Moini, MD (1)  ·  Bita Eslami, MPH (1)  ·  Caroline C Gormsen, M.D. (1)  ·  Elham Amirchaghmaghi, MD (1)  ·  Guang Ning, M.D. Ph.D. (1)  ·  Harn-Shen Chen, MD, PhD (1)  ·  Hertzel Gerstein, MD (1)  ·  Jeonghyun Park, MD PhD (1)

Results publications

PMID 16112958, PMID 16801564, PMID 16936159, PMID 19515542, PMID 19656312, PMID 21376417, PMID 22078152, PMID 23602502, PMID 23631607, PMID 24030946, PMID 24431911, PMID 24819707, PMID 24932223, PMID 25781235, PMID 27533307, PMID 27812149, PMID 28271251, PMID 28296055, PMID 28324049, PMID 28671753, PMID 28917545, PMID 29873004, PMID 31907828, PMID 32130661, PMID 32641379, PMID 33035598, PMID 34286454, PMID 35930018, PMID 36273168, PMID 40270326, PMID 40395816

NIH funding

K23DK074439 (1)